Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK
Executive Summary
There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending headwinds, GSK will be touting Shingrix for future growth as vaccines growth tempers, and Amgen treads a complicated path through the biosimilar landscape.
You may also be interested in...
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.
GSK Shingrix Shingles Vaccine Seen Displacing Zostavax After US FDA Approval
US FDA OK for its two-shot shingles regime gives GSK a likely blockbuster with a clear best-in-class profile.
Novo's Semaglutide: Retinopathy Warning Unlikely To Dim Commercial Prospects
Sponsor's proposal for a label warning, but not a black box, on retinopathy risk with the once-weekly GLP-1 agonist finds support from a US FDA advisory committee, which overwhelming endorsed approval for treatment of type 2 diabetes on the basis of robust glycemic control efficacy data and a strong cardiovascular safety profile.